Why the study?
Adriamycin causes severe cardiotoxicity that limits its clinical use, prompting this evaluation of the effectiveness and safety of Shengmai injection as a treatment.
Does Shengmai injection improve outcomes or reduce cardiotoxicity in patients with Adriamycin-related cardiotoxicity?
Does Shengmai injection improve outcomes or reduce cardiotoxicity in patients with Adriamycin-related cardiotoxicity?
This is a protocol for a systematic review and meta-analysis to evaluate the efficacy and safety of Shengmai injection for Adriamycin-related cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Protocol for meta-analysis of Shengmai injection in Adriamycin cardiotoxicity published; leaves open current evidence while enabling future synthesis.
Liu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: